Georgina completed her Honours at The University of Adelaide working on developing novel therapies for the adverse side effects of chemotherapy on the gastrointestinal tract. She then worked at the Children’s Cancer Institute in Sydney for 4 years where she assisted in discovering new therapeutic approaches for the treatment of Neuroblastoma (most common extracranial solid tumour in children). During her time at the Children’s Cancer Institute, she was involved in the Zero Childhood Cancer national clinical trial. This trial aims to develop personalised cancer treatment strategies for children, throughout Australia, with high-risk or relapsed cancer.
In mid-2018, Georgina returned to Adelaide to work as an EMBL Australia Research Officer in David Lynn’s Infection & Immunity group at SAHMRI. She is assisting in projects investigating the interplay between the microbiota and the immune system.
Murray J, +4, Eden GL, +14, Fletcher JI, Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma growth and sensitises to irinotecan in vivo, Eur J Cancer, 2017 Sep;83: 132-141
Bajic JE, Eden GL, Lampton LS, Cheah KY, Lymn KA, Pei JV, Yool AJ and Howarth GS, Rhubarb extract partially improves mucosal integrity in chemotherapy-induced mucositis, World J Gastroenterol, 2016 Oct 7; 22(37): 8322-8333
Mashtoub S, Lampton LS, Eden GL, Cheah KY, Lymn KA, Bajic JE and Howarth GS, Emu oil combined with Lyprinol™ reduces small intestinal damage in a rat model of chemotherapy-induced mucositis, Nutr Cancer, 2016 Oct; 68(7);1171